Antiviral therapy using lamivudine and thymosin α1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection

Hepato-Gastroenterology

Volumn 53, Issue 68, 2006, Pages 249-252

  Cheng, Shuqun ^a   Wu, Mengchao ^a   Chen, Han ^a   Shen, Feng ^a   Yang, Jiahe ^a   Cong, Wenming ^a   Yin, Zhengfeng ^a   Zhao, Yuxiang ^a   Wang, Peijun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti virus therapy; Hepatitis; Hepatocellular carcinoma; Recurrence

Indexed keywords

CARBOPLATIN; DOXORUBICIN; EPIRUBICIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MITOMYCIN; THYMOSIN ALPHA1;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEROCONVERSION; SURVIVAL TIME; TECHNIQUE; TUMOR RECURRENCE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE; THYMOSIN;

EID: 33645569173     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chen H, Wu MC: Selection of therapies on recurrence of primary liver cancer after hepatectomy. Chin Med J 1997; 77:163-164.
2. Wu MC, Chen H, Shen F: Surgical treatment of primary liver cancer- reported 5524 patients. Chin J Surg 2001; 39:25-28.
3. Zhou XD, Yu YQ, Tang ZY, et al: Surgical treatment of recurrent hepatocellular carcinoma. Hepatogastroenterology 1993; 40:333-336.
4. Adachi E, Maeda T, Matsumata T, et al: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108:768-775.
5. Tang ZY: Recurrence and metastasis- a key point in primary liver cancer research. J Hepatobil Surg 1999; 5:3-5.
6. Wang ET, Chew YP, Lee LA, Lee CGL: Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma. Current Drug Targets 2002; 3:369-378.
7. Lok AS: Hepatitis B infection: pathogenesis and management. J Hepatol 2000; 32(1 Suppl):89-97.
8. Core working Party for Asia-pacific consensus on Hepatitis B and C: Consensus statements on the prevention and management of hepatitis B and C in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15:824-841.
9. Leung NYW, Liaw F, Chang TT, et al: Durable HBeAg response in Chinese patients treated with Lamivuding. Hepatology 2001; 34:34:348A.
10. Malik AH, Lee WM: Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723-731.
11. Liaw YF, Leung NW, Chang TT, et al: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. Gastroenterol 2000; 119:172-180.
12. Pramoolsinsup C: Management of viral hepatitis B. J Gastroenterol Hepatol 2002; 17(Suppl):s125-s145.
13. 1 potently augments T lymphocyte response of hydrocortisone-treated aged mice. In J Immunopharmacol 1995; 17:821-828.
14. 1 stimulates maturation of CD34+ stem cells CD3+CD4+ cells in an in vitro thymic epithelia organ coculture model. In J Immonopharmocol 1999; 21:15-16.
15. Serrate SA, Schulof RS, Leondaridis L, et al: Modulation of human nature killer cell cytotoxic activity: lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 1987; 139:2338-2343.
16. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27:1383-1387.
17. Bepler G: Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review. Cancer Invest 1994; 12:491-496.
18. Pica F, Fraschetti M, Matteucci C, et al: High doses of thymosin alpha1 enhance the anti-tumor efficacy of combination chemoimmunotherapy for murine B16 melanoma. Anticancer Res 1998; 18:3571-3578.
19. 1 in patients with chronic hepatitis B. A randomized, controlled trial. Hepatology 1998; 27:1383-1387.
20. Lui ZY, Ren ZG, Xia JL, et al: Evaluation of therapeutic effects of TACE on primary liver cancer after radical resections. Chin J Tumor 2000; 22:315-317.
21. Zhou WP, Wu MC, Chen H, et al: Influence of recurrence after hepatectomy plus immunotherapy on primary liver cancer. Chin J Surg 1995; 33:35-37.
22. Camma C, Giunta M, Andreone P, et al: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: and evidence-based approach. J Hepatol 2001; 34:593-602.